IP Library › Granted Patent US 12,502,426
Granted Patent B2
US 12,502,426 · App. 17/783,478 · Granted Dec 23, 2025

Inactivated piscine orthoreovirus vaccine

Inventors: Johanna Jacoba Elisabeth Bijlsma (Nijmegen, NL); Sven Leininger (Bergen, NO); Stephane Villoing (Bergen, NO)
Assignee: Intervet Inc.
A61K39/15A61K47/22A61K2039/552
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,502,426
App. No.
17/783,478
Granted
Dec 23, 2025
Kind
B2
Abstract

The invention derives from the discovery that the immunogenicity of piscine orthoreovirus (PRV) can be significantly increased by inactivating the virus in a way different from the prior art: by incubation with an aziridine the vaccine potency against challenge infection by cohabitation is much improved over prior art approaches. This allowed the development of an effective inactivated vaccine against infection and disease caused by PRV.

Claims (19)

1 . A composition comprising an inactivated orthoreovirus, that has been inactivated by incubation with an aziridine, wherein the orthoreovirus is piscine orthoreovirus (PRV).

2 . The composition of claim 1 , wherein the aziridine is ethylenimine.

3 . A vaccine for fish against infection or disease caused by piscine orthoreovirus (PRV), comprising the composition of claim 2 , and a pharmaceutically acceptable carrier.

4 . A method of protecting a fish against infection or disease caused by piscine orthoreovirus (PRV) comprising administering the vaccine of claim 3 , to said fish.

5 . A vaccine for fish against infection or disease caused by piscine orthoreovirus (PRV), comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

6 . The vaccine of claim 5 , that comprises an adjuvant.

7 . A method of protecting a fish against infection or disease caused by piscine orthoreovirus (PRV) comprising administering the vaccine of claim 6 , to said fish.

8 . A method of protecting a fish against infection or disease caused by piscine orthoreovirus (PRV), comprising administering the vaccine of claim 5 to said fish.

9 . A method of manufacturing a vaccine to protect a fish against infection or disease caused by piscine orthoreovirus (PRV), comprising formulating the composition of claim 1 .

10 . A vaccine for fish against infection or disease caused by piscine orthoreovirus (PRV), comprising a composition obtainable by the method of claim 1 , and a pharmaceutically acceptable carrier.

11 . A method of protecting a fish against infection or disease caused by piscine orthoreovirus (PRV), comprising administering the vaccine of claim 10 to said fish.

12 . A method of producing a composition comprising aziridine-inactivated piscine orthoreovirus (PRV), comprising the steps of:

a. obtaining a composition comprising PRV, and

b. inactivating the PRV in said composition by incubation with an aziridine.

13 . The method of claim 12 , wherein the aziridine is ethylenimine or binary ethylenimine.

14 . A method of manufacturing a vaccine to protect a fish against infection or disease caused by piscine orthoreovirus (PRV), comprising formulating the composition obtainable by the method of claim 13 into a vaccine.

15 . A vaccine for fish against infection or disease caused by piscine orthoreovirus (PRV), comprising a composition obtainable by the method of claim 13 , and a pharmaceutically acceptable carrier.

16 . A method of manufacturing a vaccine to protect a fish against infection or disease caused by piscine orthoreovirus (PRV), comprising formulating the composition obtainable by the method of claim 12 into a vaccine.

17 . A vaccine for fish against infection or disease caused by piscine orthoreovirus (PRV), comprising a composition obtainable by the method of claim 12 , and a pharmaceutically acceptable carrier.

Assignments (5)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2022
From: BIJLSMA, JOHANNA JACOBA ELISABETH
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 060145/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2022
From: LEININGER, SVEN; VILLOING, STEPHANE
To: MSD ANIMAL HEALTH INNOVATION
Reel/Frame 060145/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2022
From: INTERVET INTERNATIONAL B.V.
To: INTERVET INC.
Reel/Frame 060146/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2022
From: MSD ANIMAL HEALTH INNOVATION
To: INTERVET INTERNATIONAL B.V
Reel/Frame 060146/0162 →
Priority Claims (1)
EP 19216504 · Dec 16, 2019 · regional
Continuity (1)
Related Publication 20230105140A1 · Apr 6, 2023
References Cited (35)
CA 2988038A1 · 2019 [cited by applicant]
JP 2017029102A · 2017 [cited by applicant]
RU 2401665C2 · 2010 [cited by applicant]
RU 2491339C2 · 2013 [cited by applicant]
RU 2633058C2 · 2017 [cited by applicant]
WO 9845415A1 · 1998 [cited by applicant]
WO 9851660A1 · 1998 [cited by applicant]
WO WO2005039501A2 · 2005 [cited by applicant]
WO WO2005039501A3 · 2005 [cited by applicant]
WO WO2005040353A2 · 2005 [cited by applicant]
WO WO2005040353A3 · 2005 [cited by applicant]
WO 2005121325A1 · 2005 [cited by applicant]
WO WO2008076371A2 · 2008 [cited by applicant]
WO WO2008076371A3 · 2008 [cited by applicant]
WO 2011041789A1 · 2011 [cited by applicant]
WO WO2012018973A1 · 2012 [cited by applicant]
WO 2015028565A1 · 2015 [cited by applicant]
WO 2015185605A1 · 2015 [cited by applicant]
WO 2016075277A1 · 2016 [cited by applicant]
WO WO2018140766A2 · 2018 [cited by applicant]
WO WO2018140766A3 · 2018 [cited by applicant]
Efimova et al. (Russian Agricultural Sciences. 2014; vol. 40 (No. 2): pp. 153-156). [cited by examiner]
El-Khair et al. (Egyptian Journal of Agricultural Research. Sep. 1, 2004; 82 (3): 1429-1437). [cited by examiner]
Wu, Yung Fu et al., Characterization of interleukin-1beta mRNA expression in chicken macrophages in response to avian reovirus, Journal of General Virology, 89, 1059-1068, 2008. [cited by applicant]
Bahnemann, H.G., Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine, Vaccine, 1990, pp. 299-303, vol. 8. [cited by applicant]
Bjorgen, Havard et al., Piscine orthoreovirus (PRV) in red and melanised foci in white muscle of Atlantic salmon ( [cited by applicant]
Chen, Weisan et al., Modification of Cysteine Residues In Vitro and In Vivo Affects the Immunogenicity and Antigenicity of Major Histocompatibility Complex Class I-restricted Viral Determinants, The Journal of Experimen… [cited by applicant]
Delrue, Iris et al., Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges, Expert Review of Vaccines, 2012, 695-719, 11(6). [cited by applicant]
James, Kevin T., Novel High-throughput Approach for Purification of Infectious Virions, Scientific Reports, 2016, 1-11, 6. [cited by applicant]
Kibenge, F.Sb., Emerging viruses in aquaculture, Current opinion in Virology, 2019, pp. 97-103, 34. [cited by applicant]
Markussen, T. et al., Sequence Analysis of the Genome of Piscine Orthoreovirus (PRV) Associated with Heart and Skeletal Muscle Inflammation (HSMI) in Atlantic Salmon ( [cited by applicant]
Palacios, G. et al., Heart and Skeletal Muscle Inflammation of Farmed Salmon is Associated with Infection with a Novel Reovirus, PLOS One, 2010, e11487, 5(7). [cited by applicant]
Wessel, O. et al., Inactivated Piscine orthoreovirus vaccine against heart and skeletal muscle inflammation in Atlantic salmon, Journal of Fish Diseases, 2018, pp. 1411-1419, 41. [cited by applicant]
Wessel, O. et al., Infection with purified Piscine orthoreovirus demonstrates a causal relationship with heart and skeletal muscle inflammation in Atlantic salmon, PLOS One, 2017, e0183781, 12(8). [cited by applicant]
Wessel, O., et al., Antiviral Responses and Biological Consequences of Piscine orthoreovirus Infection in Salmonid Erythrocytes, Frontiers in Immunology—Mini review, 2019, Article 3182, vol. 9. [cited by applicant]